BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 26012361)

  • 1. Combined assessment of WT1 and BAALC gene expression at diagnosis may improve leukemia-free survival prediction in patients with myelodysplastic syndromes.
    Minetto P; Guolo F; Clavio M; De Astis E; Colombo N; Grasso R; Fugazza G; Sessarego M; Lemoli RM; Gobbi M; Miglino M
    Leuk Res; 2015 Aug; 39(8):866-73. PubMed ID: 26012361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BAALC and WT1 expressions from diagnosis to hematopoietic stem cell transplantation: consecutive monitoring in adult patients with core-binding-factor-positive AML.
    Yoon JH; Kim HJ; Shin SH; Yahng SA; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Lim JH
    Eur J Haematol; 2013 Aug; 91(2):112-21. PubMed ID: 23672350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of WT1 and PRAME predicts poor outcomes of patients with myelodysplastic syndromes with thrombocytopenia.
    Huang QS; Wang JZ; Qin YZ; Zeng QZ; Jiang Q; Jiang H; Lu J; Liu HX; Liu Y; Wang JB; Su L; Zhang HY; Li ZL; Gao SJ; Huang B; Liu YY; Liu YR; Xu LP; Huang XJ; Zhang XH
    Blood Adv; 2019 Nov; 3(21):3406-3418. PubMed ID: 31714962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes.
    Cilloni D; Gottardi E; Messa F; Fava M; Scaravaglio P; Bertini M; Girotto M; Marinone C; Ferrero D; Gallamini A; Levis A; Saglio G;
    J Clin Oncol; 2003 May; 21(10):1988-95. PubMed ID: 12743153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal time-points for detecting expression levels of BAALC, EVI1, and WT1 genes in patients with acute myeloid leukemia: a meta-analysis.
    Yuen KY; Lin XY; Zhou YZ; Luo H; Liu Y; Xu LH
    Hematology; 2021 Dec; 26(1):995-1006. PubMed ID: 34871539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BAALC overexpression retains its negative prognostic role across all cytogenetic risk groups in acute myeloid leukemia patients.
    Damiani D; Tiribelli M; Franzoni A; Michelutti A; Fabbro D; Cavallin M; Toffoletti E; Simeone E; Fanin R; Damante G
    Am J Hematol; 2013 Oct; 88(10):848-52. PubMed ID: 23760853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromes.
    Thol F; Yun H; Sonntag AK; Damm F; Weissinger EM; Krauter J; Wagner K; Morgan M; Wichmann M; Göhring G; Bug G; Ottmann O; Hofmann WK; Schambach A; Schlegelberger B; Haferlach T; Bowen D; Mills K; Ganser A; Heuser M
    Ann Hematol; 2012 Aug; 91(8):1221-33. PubMed ID: 22488406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of WT1 mRNA and anti-WT1 antibody levels in peripheral blood in patients with myelodysplastic syndromes.
    Tamura H; Dan K; Yokose N; Iwakiri R; Ohta M; Sakamaki H; Tohyama K; Kondo A; Hyodo H; Nakamura K; Yamashita T; Elisseeva OA; Oka Y; Oji Y; Sugiyama H; Ogata K
    Leuk Res; 2010 Aug; 34(8):986-90. PubMed ID: 20031209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wilms Tumor 1 (WT1) mRNA Expression Level at Diagnosis Is a Significant Prognostic Marker in Elderly Patients with Myelodysplastic Syndrome.
    Nagasaki J; Aoyama Y; Hino M; Ido K; Ichihara H; Manabe M; Ohta T; Mugitani A
    Acta Haematol; 2017; 137(1):32-39. PubMed ID: 27866185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combinatorial molecular marker assays of WT1, survivin, and TERT at initial diagnosis of adult acute myeloid leukemia.
    Kim HJ; Choi EJ; Sohn HJ; Park SH; Min WS; Kim TG
    Eur J Haematol; 2013 Nov; 91(5):411-22. PubMed ID: 23826993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IPSS-R in 555 Taiwanese patients with primary MDS: Integration of monosomal karyotype can better risk-stratify the patients.
    Yang YT; Hou HA; Liu CY; Lin CC; Chou WC; Lee FY; Liu MC; Liu CW; Tang JL; Yao M; Li CC; Kuo YY; Huang SY; Ko BS; Chen CY; Hsu SC; Lin CT; Wu SJ; Tsay W; Chen YC; Tien HF
    Am J Hematol; 2014 Sep; 89(9):E142-9. PubMed ID: 24845799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. WT1 gene expression: useful marker for minimal residual disease in childhood myelodysplastic syndromes and juvenile myelo-monocytic leukemia?
    Bader P; Niemeyer C; Weber G; Coliva T; Rossi V; Kreyenberg H; Gerecke A; Biondi A
    Eur J Haematol; 2004 Jul; 73(1):25-8. PubMed ID: 15182334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of pretransplant measurable residual disease assessed by peripheral blood WT1-mRNA expression in patients with AML and MDS.
    Rautenberg C; Lauseker M; Kaivers J; Jäger P; Fischermanns C; Pechtel S; Haas R; Kobbe G; Germing U; Schroeder T
    Eur J Haematol; 2021 Aug; 107(2):283-292. PubMed ID: 33987857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of Acute Myeloid Leukemia Progression on the Prognosis of 831 Patients With Myelodysplastic Syndromes From the Argentine Database.
    Enrico A; Bestach Y; Flores MG; Arbelbide J; Serale C; Novoa V; Crisp R; Rivas MM; Larripa I; Belli C
    Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):743-752.e5. PubMed ID: 28797621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low MDR1 and BAALC expression identifies a new subgroup of intermediate cytogenetic risk acute myeloid leukemia with a favorable outcome.
    Guo X; Shi P; Chen F; Zha J; Liu B; Li R; Dong H; Zheng H; Xu B
    Blood Cells Mol Dis; 2014 Sep; 53(3):144-8. PubMed ID: 24855032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wilms' tumor 1 message and protein expression in bone marrow failure syndrome and acute leukemia.
    Iwasaki T; Sugisaki C; Nagata K; Takagi K; Takagi A; Kojima T; Ito M; Nakamura S; Naoe T; Murate T
    Pathol Int; 2007 Oct; 57(10):645-51. PubMed ID: 17803653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. WT1 expression levels at diagnosis could predict long-term time-to-progression in adult patients affected by acute myeloid leukaemia and myelodysplastic syndromes.
    Galimberti S; Ghio F; Guerrini F; Ciabatti E; Grassi S; Ferreri MI; Petrini M
    Br J Haematol; 2010 May; 149(3):451-4. PubMed ID: 20085581
    [No Abstract]   [Full Text] [Related]  

  • 18. Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AML.
    Nomdedéu JF; Hoyos M; Carricondo M; Bussaglia E; Estivill C; Esteve J; Tormo M; Duarte R; Salamero O; de Llano MP; García A; Bargay J; Heras I; Martí-Tutusaus JM; Llorente A; Ribera JM; Gallardo D; Aventin A; Brunet S; Sierra J;
    Leukemia; 2013 Nov; 27(11):2157-64. PubMed ID: 23584566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes.
    Duong VH; Padron E; Al Ali NH; Lancet JE; Hall J; Kwok B; Zhang L; Epling-Burnette PK; List AF; Komrokji RS
    Ann Hematol; 2018 Feb; 97(2):247-254. PubMed ID: 29167940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia.
    Díaz-Beyá M; Brunet S; Nomdedéu J; Cordeiro A; Tormo M; Escoda L; Ribera JM; Arnan M; Heras I; Gallardo D; Bargay J; Queipo de Llano MP; Salamero O; Martí JM; Sampol A; Pedro C; Hoyos M; Pratcorona M; Castellano JJ; Nomdedeu M; Risueño RM; Sierra J; Monzó M; Navarro A; Esteve J
    Blood Cancer J; 2015 Oct; 5(10):e352. PubMed ID: 26430723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.